

1 Additional file 2. Table S1. Demographic and clinical characteristics of study subjects (mycobiome) (n=68)

Variables	CON (n=16)	Untreated (n=22)	asthma	ICS asthma (n=30)
Age, years, mean $\pm$ SD	38.2 $\pm$ 9.6	42.45 $\pm$ 14.8		44.86 $\pm$ 15.7
Male, no. (%)	6(37.5)	9(40.9)		11(36.6%)
BMI, kg/m ² , mean $\pm$ SD	22.2 $\pm$ 2.9	24.2 $\pm$ 3.9		22.7 $\pm$ 3.0
Duration of asthma, years, mean $\pm$ SD)	-	2.3 $\pm$ 6.5		10.8 $\pm$ 16.6###
Rhinosinusitis, no. (%)	0(0)	15(68.1) ***		17(56.6)
ICS dose ¹ , μ g.day ⁻¹ , mean $\pm$ SD	-	-		569.6 $\pm$ 302.9
FEV1 (% predicted), mean $\pm$ SD	95 $\pm$ 9.5	72.1 $\pm$ 22.6***		82.8 $\pm$ 17.6
FEV1/FVC (%), mean $\pm$ SD	82.5 $\pm$ 7.7	70.1 $\pm$ 10.3**		75.2 $\pm$ 12.9
ACQ7 score, mean $\pm$ SD	-	1.3 $\pm$ 0.8		0.7 $\pm$ 0.5##
Sputum eosinophils (EOS%), mean $\pm$ SD	1 $\pm$ 1.3	2.9 $\pm$ 2.7		2.0 $\pm$ 2.5
Sputum neutrophils (NEU%), mean $\pm$ SD	27.3 $\pm$ 23.7	21.8 $\pm$ 19.5		17.4 $\pm$ 16.0
Total IgE, IU/mL, mean $\pm$ SD	44.1 $\pm$ 16.6	157.6 $\pm$ 117.0 ***		155.2 $\pm$ 72.6

2 ¹ ICS dose was expressed as beclomethasone propionate equivalent dose. Naïve asthma group vs CON group: **p<0.01, ***p<0.001. ICS asthma
3 group vs naïve asthma group: ## p<0.01 ### p<0.001.